In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management.
In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.
Chapters:
00:00 - Intro
00:40 - Abbott OTC CGM
06:20 - Diabetes Technology Pipeline
10:45 - JDRF Rebrands as Breakthrough T1D
15:15 - US FDA Clearance of CamAPS FX
All content for Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is the property of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management.
In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.
Chapters:
00:00 - Intro
00:40 - Abbott OTC CGM
06:20 - Diabetes Technology Pipeline
10:45 - JDRF Rebrands as Breakthrough T1D
15:15 - US FDA Clearance of CamAPS FX
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management.
In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.
Chapters:
00:00 - Intro
00:40 - Abbott OTC CGM
06:20 - Diabetes Technology Pipeline
10:45 - JDRF Rebrands as Breakthrough T1D
15:15 - US FDA Clearance of CamAPS FX
